


Large and Proven Hepatitis C Market

Hepatitis C Market

- Large patient population
 - 130 million patients today
 - Non-responders drive future growth
- Current standard of care is pegylated interferon alfa + ribavirin
- Interferon alfa is expected to be the platform for future treatments
- **Interferon has burdensome side effects**
 - **Patient treatment and compliance rates are currently low**
- **New agents such as VX-950 add their own side effect burden**

Interferon Alfa WW Market for HCV



Source: Decision Resources / Kalorama Information

Locteron's efficacy / tolerability advantages will be used to position it as the "interferon of choice" regardless of the combination